证券代码：688271 证券简称：联影医疗 公告编号：2024-019 上海联影医疗科技股份有限公司 股东询价转让计划书 上海中科道富投资合伙企业（有限合伙）（以下简称"中科道富"）、上海 北元投资合伙企业（有限合伙）（以下简称"北元投资"，与中科道富以下合称 "出让方"）保证向上海联影医疗科技股份有限公司（以下简称"公司"或"联 影医疗"）提供的信息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 1 拟参与联影医疗首发前股东询价转让（以下简称"本次询价转让"）股 东为中科道富、北元投资； 出让方拟转让股份的总数为 9,000,000 股，占联影医疗总股本的比例为 1.09%； 本次询价转让不通过集中竞价交易或大宗交易方式进行，不属于通过 二级市场减持。受让方通过询价转让受让的股份，在受让后 6 个月内 不得转让； 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投 资者。 股东中科道富、北元投资所持股份自 2023 年 8 月 22 日起上市流通， 至今未发生任何减 ...

Investment Rating - The investment rating for the company is "Accumulate" [4][19]. Core Views - The company demonstrated resilience in its performance with a revenue of 11.41 billion yuan (+23.52%) and a net profit of 1.97 billion yuan (+19.21%) in 2023, despite industry adjustments [5][19]. - The company is expected to continue its growth trajectory with projected revenues of 13.93 billion yuan, 16.81 billion yuan, and 20.25 billion yuan for 2024, 2025, and 2026 respectively, reflecting year-on-year growth rates of 22.0%, 20.7%, and 20.5% [19][21]. Summary by Sections Financial Performance - In 2023, the company achieved a revenue of 11.41 billion yuan (+23.52%) and a net profit of 1.97 billion yuan (+19.21%). The fourth quarter of 2023 saw a revenue of 3.98 billion yuan (+17.72%) and a net profit of 910 million yuan (+20.17%) [5][19]. - The first quarter of 2024 reported a revenue of 2.35 billion yuan (+6.22%) and a net profit of 363 million yuan (+10.20%) [5][19]. Product Sales and Services - Equipment sales grew steadily, with a total revenue of 9.93 billion yuan (+21.1%) in 2023. The revenue from CT, MR, MI, XR, and RT product lines increased by 7.8%, 58.5%, 1.4%, 32.8%, and 6.9% respectively [11][19]. - The maintenance service business saw rapid growth, achieving a revenue of 1.07 billion yuan (+42.8%), accounting for 9.4% of total revenue [11][19]. - Software business revenue surged to 174 million yuan (+124.85%), driven by digitalization efforts and a low base from the previous year [11][19]. Market Expansion - The domestic market revenue reached 9.73 billion yuan (+22%), while international market revenue grew by 56% to 1.68 billion yuan, increasing its share to 15% [14][19]. - The company has made significant strides in international markets, with 45 products obtaining CE certification and 44 products passing FDA 510(k) registration, covering over 65 countries and regions [14][19]. Cost and Margin Analysis - The gross margin for 2023 was 48.48% (+0.12 percentage points), with increases in the proportion of mid-to-high-end product sales and maintenance services [2][19]. - The total expense ratio increased to 34.26% (+2.16 percentage points), driven by higher sales, management, and R&D expenses as the company invests in technology and talent [2][19].

证券研究报告 | 2024年05月15日 联影医疗（688271.SH） 增持 业绩增长显韧性，国际市场持续开拓 核心观点 公司研究·财报点评 业绩实现较快增长，彰显发展韧性。2023 年公司实现营收 114.11 亿元 医药生物·医疗器械 （+23.52%），归母净利润19.74亿元（+19.21%），扣非归母净利润16.65 证券分析师：张佳博 联系人：凌珑 亿元（+25.38%）。其中23Q4单季营收39.78亿元（+17.72%），归母 021-60375487 021-60375401 zhangjiabo@guosen.com.cnlinglong@guosen.com.cn 净利润9.10亿元（+20.17%），扣非归母净利润8.36亿元（+37.55%）。 S0980523050001 在行业整顿背景下，公司2023年业绩实现较快增长，彰显发展韧性。 基础数据 分季度看，三季度由于受到行业整顿的影响，收入和利润规模较二季度 投资评级 增持(维持) 环比下降，四季度随着行业整顿影响减弱及配置证放宽政策的逐步落 合理估值 收盘价 135.68元 地，业绩实现环比和同比增长。2024年一季度营收23 ...

Investment Rating - The report assigns a rating of "Outperform" for the company, indicating an expected total return performance exceeding the benchmark index by more than 10% over the next 12 months [1][10]. Core Insights - The company reported a revenue of RMB 11.4 billion for 2023, representing a year-on-year growth of 23.5%, and a net profit of RMB 1.97 billion, up 19.2% year-on-year, which aligns with expectations [4][5]. - In Q1 2024, the company achieved a revenue of RMB 2.4 billion, a 6.2% increase year-on-year, with a net profit of RMB 360 million, reflecting a 10.2% growth [4]. - The company has expanded its market presence both domestically and internationally, with over 1,000 top-tier hospitals in China and operations in more than 65 countries [4]. - The company ranks first in the domestic market for PET/CT, PET/MR, and XR products, with significant growth in high-end and ultra-high-end products [4]. - The global service network has been enhanced, with over 1,000 service personnel and extensive training programs, improving operational capabilities [4]. Financial Summary - Revenue projections for 2024, 2025, and 2026 are RMB 14.4 billion, RMB 18.3 billion, and RMB 23.4 billion, respectively [5]. - Expected net profits for the same years are RMB 2.37 billion, RMB 2.86 billion, and RMB 3.38 billion, with a current PE ratio of 47 for 2024 [5]. - The company’s revenue growth rates are projected at 26.4%, 26.9%, and 27.9% for 2024, 2025, and 2026, respectively [7][8]. Market Position - The company has established a strong foothold in the high-end medical equipment market, with significant recognition from clinical institutions across various levels [4]. - The international revenue share has increased by 2.96 percentage points year-on-year, indicating robust growth in overseas markets [4]. Valuation - The report maintains a valuation outlook based on projected revenue and profit growth, reinforcing the "Outperform" rating [5].

参会嘉宾:实控人、联席首席执行官、总裁、首席财务官、董事会秘书 公司财务情况介绍 各项指标保持稳健增长，2023 年收入 114.11 亿元（+23.52%）；归母净利润 19.74 亿元（+19.21%）；扣 非净利润 16.65 亿元（+23.38%）。23Q4 收入 39.78 亿元（+17.72%）；归母净利润 9.10 亿元 （+20.17%）；扣非净利润 8.36 亿元（+37.55%）。 2024Q1 收入 23.50 亿元（+6.22%）；归母净利润 3.63 亿元（+10.20%）；扣非净利润 3.00 亿元 （+8.52%）。其中，海外业务同比增长近 50%，国际市场收入占比超 15%。我们认为，24 年伴随各地医疗 设备更新细则政策逐步落地，及各级医疗机构高质量建设等需求带动，叠加海外持续拓展，公司全年增长动 力有望维持。 2023 年国内市场收入 97.33 亿元（+19.37%），国际市场收入 16.78 亿元（+54.72%），保持高速增长态 势，国际市场占收比提升至 14.7%。 2024 年一季度公司实现营业收入 23.5 亿元，同比增长 6.22%，实现归母净利润 3.03 ...

Investment Rating - The report maintains an "Overweight" rating for the company [5] Core Views - The company reported a revenue of 11.41 billion yuan in 2023, representing a year-on-year growth of 23.52%, and a net profit attributable to shareholders of 1.974 billion yuan, up 19.21% year-on-year [3][4] - The company's overseas business revenue reached 1.678 billion yuan in 2023, a significant increase of 55.69% year-on-year, accounting for 14.70% of total revenue, which is an increase of 2.96 percentage points year-on-year [4] - The company is expected to see continued growth in earnings per share (EPS), with projections of 2.90 yuan, 3.53 yuan, and 4.34 yuan for 2024, 2025, and 2026 respectively, corresponding to price-to-earnings (P/E) ratios of 46.5, 38.1, and 31.0 based on the closing price on May 7, 2024 [5] Financial Performance Summary - In 2023, the company achieved a gross margin of 48.48%, a slight increase of 0.11 percentage points year-on-year, driven by the rising proportion of high-end products [4] - The company's operating cash flow for 2023 was 133 million yuan, a decrease of 80.59% year-on-year [3] - The company’s revenue from MR products grew by 58.50% year-on-year, while XR products saw a growth of 32.83% [4] - The company’s total assets were reported at 25.35 billion yuan, with net assets of 19.23 billion yuan as of the latest report [2]

M N 2024 年 4 月 29日 招银国际环球市场 | 睿智投资 | 公司更新 联影医疗 (688271 CH) 高端市场持续拓展，国际化战略快速推进 目标价 160.39人民币 2023年公司实现营收114.1亿元，同比增长23.5%；归母净利润19.7亿元，同比增 (此前目标价 161.42人民币) 长19.2%，毛利率略微提升至48.5%（+0.1ppts），我们认为主要得益于中高端产品 潜在升幅 24.2% 和服务收入占比的提高，以及生产、物流等环节运营效率的提升。归母净利率下降 当前股价 129.10人民币 0.6 个百分点，主要是由于公司积极拓展海外业务并持续加大研发投入，销售费用率 中国医药 和研发费用率有所上升。1Q24，公司保持稳健增长，实现营业收入 23.5亿元，同比 武 煜, CFA 增长6.2%；归母净利润3.6亿元，同比增长10.2%。 (852) 3900 0842  设备销售稳步增长，中高端产品表现亮眼。2023 年公司设备销售收入 99.3 亿 jillwu@cmbi.com.hk 元，同比增长 21.1%，各产线收入和销量均实现增长。1）CT：2023 年产线收 王云逸 ...

Investment Rating - The report does not specify a clear investment rating for the company [1] Core Views - The company reported a revenue of 11.41 billion yuan in 2023, representing a year-on-year increase of 23.5%, and a net profit of 1.97 billion yuan, up 19.2% [2] - The first quarter of 2024 showed a revenue of 2.35 billion yuan, an increase of 6.2%, and a net profit of 360 million yuan, up 10.2% [2] - The growth in revenue is driven by both domestic and international markets, with domestic revenue at 9.5 billion yuan (+19.7%) and overseas revenue at 1.7 billion yuan (+54.0%) [2] - The company has expanded its business network to cover 65 countries and regions globally, with over 700 product registrations and certifications [2] - The release of restrictions on high-end medical equipment procurement is expected to accelerate demand for mid-to-high-end imaging equipment [2] Summary by Sections Financial Performance - In 2023, the revenue from medical imaging equipment was 9.93 billion yuan (+21.1%), maintenance service revenue was 1.07 billion yuan (+42.8%), and software revenue was 170 million yuan (+124.8%) [2] - The company expects revenues for 2024, 2025, and 2026 to be 13.9 billion yuan, 17.2 billion yuan, and 21.5 billion yuan respectively, with net profits of 2.4 billion yuan, 2.9 billion yuan, and 3.6 billion yuan [3][10] Business Segments - The revenue from imaging equipment is projected to grow at rates of 21% in 2024, 22% in 2025, and 24% in 2026, with a gross margin of approximately 47.8% [9] - Maintenance and technical service revenue is expected to grow at a compound annual growth rate (CAGR) of 30% from 2024 to 2026, with gross margins increasing to 65% by 2026 [9] - Software revenue is anticipated to grow at a CAGR of 50% during the same period, with a gross margin of 40% [9] Market Expansion - The company has achieved significant growth in overseas markets, with overseas revenue accounting for 14.7% of total revenue in 2023, an increase of 3 percentage points from 2022 [2] - The company has received multiple certifications, including CE and FDA approvals, enhancing its competitive position in both developed and emerging markets [2] Future Outlook - The company is expected to maintain a strong growth trajectory, with projected revenue growth rates of 22.25% in 2024, 23.42% in 2025, and 24.68% in 2026 [4] - The net profit growth rates are forecasted to be 20.92% in 2024, 22.77% in 2025, and 24.24% in 2026 [4]

证券代码：688271 证券简称：联影医疗 公告编号：2024-018 上海联影医疗科技股份有限公司 关于以集中竞价交易方式回购公司股份进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2023/8/23 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 40,000 元~80,000 元 | | 回购用途 | 用于员工持股计划或股权激励 | | 累计已回购股数 | 4,716,821 股 | | 累计已回购股数占总股本比例 | 0.57% | | 累计已回购金额 | 511,272,168.36 元 | | 实际回购价格区间 | 102.20 元/股~140.00 元/股 | 一、 回购股份的基本情况 2023 年 8 月 22 日，公司召开第一届董事会第二十二次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司以集中竞价交易方式 回购公司股份，回购资金总额不低于人民币 4 亿元（ ...

Financial Performance - In 2023, the company achieved a revenue of CNY 11.411 billion, representing a year-on-year growth of 23.52%. The net profit attributable to shareholders was CNY 1.974 billion, with a growth of 19.21%. The gross margin for 2023 was 48.48%, an increase of 0.12 percentage points compared to the previous year [2][3]. - For Q1 2024, the company reported a revenue of CNY 2.350 billion, a year-on-year increase of 6.22%, and a net profit of CNY 0.363 billion, up by 10.20% [2][3]. Revenue Distribution - In 2023, domestic revenue reached CNY 9.733 billion, growing by 19.37%, while international revenue was CNY 1.03 billion, marking a 39.7% increase. The international market revenue accounted for 14.7% of total revenue, with a significant growth of 54.72% [2][3]. - Equipment revenue for 2023 was CNY 9.927 billion, up by 21.10%, while service revenue reached CNY 1.069 billion, growing by 42.78% [3][4]. Product Line Performance - The revenue breakdown by product line in 2023 included: CT revenue of CNY 4.066 billion, MR revenue of CNY 3.279 billion, MI revenue of CNY 1.552 billion, XR revenue of CNY 0.760 billion, and RT revenue of CNY 0.270 billion. MR revenue saw a notable increase of 58.5% [3][4]. - The company maintained its leading position in the Chinese market for medical imaging and radiation therapy equipment, with significant growth in high-end and ultra-high-end CT systems [3][4]. R&D and Innovation - In 2023, the company invested CNY 1.729 billion in R&D, with a workforce of 2,956 R&D personnel, accounting for 39.73% of total employees. The R&D investment is crucial for maintaining competitiveness and growth [4][5]. - The company launched over 120 innovative products by Q1 2024, with 49 products receiving CE certification and 44 products obtaining FDA approval [5][6]. Market Expansion - By the end of 2023, the company had established partnerships with over 40 institutions across more than 30 countries, contributing to over 1,300 global research publications [7][8]. - The company’s products served over 12,600 medical institutions in more than 65 countries and regions, with a focus on enhancing medical capabilities at various levels of healthcare institutions in China [8][9]. Future Outlook - The company aims to leverage technological innovations to enhance medical quality and efficiency, focusing on high intelligence, low cost, and early health solutions in the healthcare market [13][14]. - The company plans to strengthen its management system, enrich its product portfolio, and enhance brand influence to become a global leader in medical innovation [14][15].